MRONJ-inducing drugs | Prevalence | Incidence |
---|---|---|
Oral bisphosphonates Intravenous bisphosphonates | <0.001% (0% to 0.04%) 1.0% to 2.3% for 3-year administration | 1.04 to 69 per 100,000 patient-years 0 to 12,222 per 100,000 patient-years |
Anti-RANKL antibody Osteoporosis Cancer | 1.3% to 3.2% for 3-year administration | 0 to 30.2 per 100,000 patient-years 0 to 2,316 per 100,000 patient-years |
Angiogenic inhibitors | 0.3% to 0.4% | |
Anti-sclerostin antibody | Unknown | Unknown |
Anti-TNFα antibody | ||
Anti-CD20 antibody | ||
Other monoclonal antibodies | ||
Tyrosine kinase inhibitors | ||
mTOR inhibitors |